恒瑞醫藥(600276.SH):與默沙東簽署HRS-5346項目授權許可協議
格隆匯3月25日丨恒瑞醫藥(600276.SH)公佈,公司與MerckSharp&Dohme公司(簡稱“MSD”或“默沙東”)達成協議,將恒瑞的脂蛋白(a)[Lp(a)]口服小分子項目(包括名為HRS-5346的先導化合物)有償許可給MSD,MSD將獲得HRS-5346在大中華地區以外的全球範圍內開發、生產和商業化的獨家權利。HRS-5346是一種在研的Lp(a)口服小分子抑制劑,目前正在中國進行Ⅱ期臨牀試驗。Lp(a)升高是一種遺傳決定的疾病,也是心血管疾病的獨立危險因素。全球約有14億人Lp(a)水平升高。默沙東將向恒瑞支付2億美元的首付款。恒瑞有資格獲得與開發、監管和商業化相關的里程碑付款,最高可達17.7億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.